The global Circulating Tumor Cells Market is anticipated to grow significantly in the coming years owing to the increasing number of cancer cases. Circulating tumor cells circulate inside the body through the bloodstream. They comprise seeds that are responsible for the growth of additional tumors in different organs, which cause cancer. Hence, different tumor detection markers are developed for the early discovery of cancer.
The growth of the circulating tumor cells (CTC) market is influenced by the increasing mortality rate due to cancer, several types of genetic disorders, drastic changes in lifestyle, an increase in smoking-causing disorders, and a rise in consumption of alcohol. Moreover, developments in bioengineering technologies, biomedical imaging, and the rise in demand for preventive medications for different types of cancers are also stimulating the market growth of circulating tumor cells. However, the factors restraining the market growth comprise the significant cost of detection techniques, scarcity of specific biomarkers for the detection of CTCs, reluctance in the adoption of new technologies, and other technical limits.
The increasing focus of the market players for the introduction of companion diagnostics for cancer and other disorders and the increase in demand for research projects on cancer are a few trends in the circulating tumor cells industry. The circulating tumor cells market is categorized based on technology, application, and geography. Based on technology, the market is divided into CTC Detection, CTC Enrichment, and CTC Analysis. CTC enrichment segment is expected to lead the market owing to high efficiency due to increased functionalities.
Based on application, the circulating tumor cells (CTC) industry is divided into tumorigenesis research, cancer stem cell research, EMT biomarkers development, and others.EMT biomarkers development segment is predicted to hold the maximum share of the market due to advancements in technology.
In terms of end-user, the circulating tumor cells (CTC) market is bifurcated into research & academic institutes, hospitals & clinics, and diagnostic centers. The hospitals and clinics segment is expected to hold a larger share of the market due to the increasing preference for efficient treatment offered at hospitals.
Geographically, the CTC industry is segmented as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America, followed by Europe accounted for the larger share of the market due to a large number of market players and mature healthcare infrastructure. Asia-Pacific is also expected to grow considerably in the coming years due to increasing investment and growing technological advancements in the domain.
The prominent players in the circulating tumor cells industry include ApoCell, Advanced Cell Diagnostics, Inc, ClearbridgeBiomedicsPte Ltd, Aviva Biosciences, CynvenioBiosystems, Inc, BioceptInc, MiltenyiBiotec, Menarini Silicon Biosystems, Qiagen, and CreatvMicrotech Inc.
Global Circulating Tumor Cell Technology Outlook (Revenue, USD Million, 2012 - 2022)
• CTC Enrichment
• Ex-vivo positive selection
• In-vivo positive selection
• Negative selection
• Single spiral microchannel
• CTC Detection
• Immunocytochemical technologies
• Molecular(RNA) based technologies
• EPISPOT functional in-vitro cell culture
• Functional in-vitro cell invasion assay
• Xenotransplantation models
• CTC Analysis
Global Circulating Tumor Cell Application Outlook (Revenue, USD Million, 2012 - 2022)
• Tumorigenesis research
• EMT biomarkers development
• Cancer stem cell research
Circulating Tumor Cell Regional Outlook (Revenue, USD Million, 2012 - 2022)
• North America
• the U.S.
• the UK
• the Asia Pacific
• Latin America
• South Africa
Research Support Specialist, USA
FREE sample contains market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...